Citations

Clear

3942 citation(s) found for "To, Van".

Participant Retention in a Prospective Multicenter Cohort of Participants With Pancreatitis and Factors Associated With Attrition
Choate, Radmila , Xu, Jun , Easler, Jeffrey J. , Phillips, Anna E. , Fisher, William E., Fogel, Evan L. , Forsmark, Chris E. , Hart, Phil A. , Park, Walter G. , Vege, Santhi Swaroop, Conwell, Darwin L. , Yadav, Dhiraj, Choate, Radmila , Xu, Jun , Han, Samuel , Phillips, Anna E., Bellin, Melena D. , Pandol, Stephen J. , Serrano, Jose, Van Den Eeden, Stephen K , Vege, Santhi Swaroop , Li, Liang , Conwell, Darwin L. , Yadav, Dhiraj

Mayo Clinic

Pancreas | October 13, 2025 | Volume: 55 | Issue: 2 | Pages: e162-e172

10.1097/mpa.0000000000002550 | PMID 41081560 Get It

Objectives: Participant retention is essential in prospective studies to minimize bias and maintain validity. This study aimed to estimate retention rates and identify factors influencing attrition in a multicenter cohort (PROCEED) of US adults with acute/recurrent acute pancreatitis (AP/RAP) and chronic pancreatitis (CP). Methods: Participants from the PROCEED study with AP/RAP or CP eligible for follow-up within the designated visit window were included. Retention was defined as completing at least one follow-up visit during the observation period. Retention was analyzed by follow-up mode (in-person and/or medical record review) and disease type (AP/RAP and CP). Retention factors were assessed using univariate analyses (Wilcoxon rank-sum for continuous variables, χ 2 /Fisher's exact for categorical) and multivariable logistic regression. Missing data were adjusted using multiple imputations in statistical modeling. Results: Among 1279 participants (AP/RAP: n=632, median age 47, 48.9% female; CP: n=647, median age 54, 46.5% female), we observed high cumulative and annualized retention rates, with improved retention when incorporating medical record reviews. In multivariable regression analyses, older age was statistically significantly associated with in-person retention in the AP/RAP group ( P =0.0001), while a higher self-reported physical health (assessed with PROMIS Global Health Physical Health T-score) was a key predictor of retention in CP ( P =0.034). Conclusions: Integrating medical records review substantially enhanced retention rates, enabling robust analyses of pancreatitis outcomes and disease progression. Older age and better self-reported physical health were key predictors of retention, highlighting the need for targeted strategies to enhance engagement among younger participants and those with poorer health in long-term studies.
Brachial-Ankle Pulse Wave Velocity Is Associated with Kidney Function Decline in Adults Undergoing Cardiovascular Disease Screening
Ledet, Caroline B. , Arslan, Meliksah , Dyke, Kylie Van , Malik, A. Rauoof , Kullo, Iftikhar J. , Van Dyke, Kylie, Kullo, Iftikhar J , Dyke, Kylie Van

Mayo Clinic

Kidney360 | October 10, 2025 | Volume: 7 | Issue: 2 | Pages: 291-301

10.34067/kid.0000000973 | PMID 41071605 Get It

Key Points We studied the link between brachial-ankle pulse wave velocity (baPWV) and CKD risk in adults undergoing cardiovascular disease screening. A higher baseline baPWV was predictive of an increased annualized rate of creatinine-based eGFR (eGFR Cr ) decline. Compared with normal baPWV, higher baseline baPWV was associated with increased risk of developing CKD and lower CKD-free survival time. Background CKD affects 35 million adults in the United States and is associated with high morbidity and mortality. We investigated whether brachial-ankle pulse wave velocity (baPWV), a noninvasive measure of arterial stiffness, was associated with kidney function decline in adults undergoing cardiovascular disease (CVD) screening. Methods In 1862 patients referred for an exercise electrocardiogram test between 2007 and 2009, baPWV was measured using an Omron Colin oscillometric device. Creatinine-based GFR was estimated (eGFR Cr ) for participants with available baseline and follow-up creatinine values using the CKD Epidemiology Collaboration formula. We performed multivariable linear regression analyses to assess whether baseline baPWV was associated with annualized change in eGFR Cr , after adjustment for age, sex, body mass index, baseline eGFR Cr , and traditional CVD risk factors, including mean arterial pressure, diabetes and hypertension diagnoses, nephroprotective medication use, smoking status, and total cholesterol. To determine risk of developing CKD and CKD-free survival time by arterial stiffness subgroups, we performed covariable-adjusted Cox proportional hazards modeling and a Kaplan-Meier survival analysis, respectively. Results After exclusion of participants with missing covariable data and adjustment for covariables, one SD increase in baPWV was associated with a 0.18 ml/min per 1.73 m 2 BSA greater yearly decrease in eGFR Cr ( P = 0.023) over a median follow-up time of 13.2 years. Participants with higher baseline baPWV had increased risk of CKD (hazard ratio [95% confidence interval], P value; elevated baPWV: 2.4 [1.1 to 5.4], P = 0.037; borderline-elevated baPWV: 1.8 [1.1 to 3.1], P = 0.028) and had a shorter CKD-free survival time (median CKD-free survival time [years]; normal baPWV: 16.2; borderline-elevated baPWV: 16.0; elevated baPWV: 15.6 [ P < 0.001]). Conclusions Elevated baPWV, a noninvasive measure of arterial stiffness that can be obtained in the office setting, was associated with decline in kidney function, risk of CKD development, and CKD-free survival in individuals undergoing CVD screening.
Vilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial
Giamarellos‐Bourboulis, Evangelos J. , Jemec, Gregor B. E. , Prens, Errol P. , Riedemann, Niels C. , Otto, Isabella , Weisman, Jamie, Pulka, Grażyna, Nowicki, Roman , Kantardjiev, Vessel, Pinter, Andreas , Berneman, Debra, Breno, Brigitte, Stone, Melody L., Anadkat, Milan J. , Papakonstantis, Markos, Bécherel, Pierre‐André, Szepietowski, Jacek C. , Nowicki, Roman J , Thomsen, Simon Francis , Kanni, Theodora , Alavi, A , Gooderham, Melinda J , Anadkat, Milan J , Katoulis, Alexandros , Papakonstantis, Markos , Becherel, Pierre-André , Szepietowski, Jacek C , van der Zee, Hessel H , Zouboulis, Christos C , Sayed, Christopher , Jemec, G B E , Pinter, A , Giamarellos-Bourboulis, Evangelos J , Otto, Isabell, Alavi, Afsáneh , Gooderham, Melinda , Zee, Hessel H. van der , Zouboulis, Christos C. , Sayed, Christopher J.

Mayo Clinic

British Journal of Dermatology | October 10, 2025 | Volume: 194 | Issue: 2 | Pages: 254-263

10.1093/bjd/ljaf398 | PMID 41081529 Get It

Abstract Background The results of a previous phase IIa trial suggested efficacy of the anti-C5a compound vilobelimab in a small number of patients with severe hidradenitis suppurativa (HS) refractory to adalimumab treatment. Objectives To study the efficacy of vilobelimab in a larger-scale randomized phase IIb trial (SHINE) of patients with moderate-to-severe HS. Methods In total, 177 patients with moderate-to-severe HS were treated either with placebo or one of four doses of vilobelimab, a monoclonal antibody that targets the complement split product C5a. Hidradenitis Suppurativa Clinical Response (HiSCR) at 16 weeks was the primary endpoint. Those who achieved HiSCR switched to open-label low-dose vilobelimab; those who did not were switched to medium-dose vilobelimab. The trial was registered with the EU Clinical Trials Register (EudraCT number 2017-004501-40) and ClinicalTrials.gov (NCT03487276). Results The study did not meet the primary endpoint, perhaps due, in part, to an unexpectedly high HiSCR placebo response rate of 47.1%. HS flares decreased and post hoc analysis showed that high-dose vilobelimab significantly decreased the median draining tunnel counts and IHS4 score by 63%. Following the switch to medium-dose vilobelimab at week 16, 45.5% of those who did not respond to treatment achieved HiSCR at week 40. Conclusions Compared with placebo, vilobelimab treatment did not result in significant HiSCR improvements in patients with moderate-to-severe HS. Post hoc analysis revealed significant effects for the highest tested dose on draining tunnel reduction and IHS4 score, which captures reductions in draining tunnels. These findings warrant further investigation.
Beyond BRCA deficiency: Clinical and molecular predictors of survival in patients with BRCA-deficient tubo-ovarian high-grade serous carcinoma
Garsed, Dale W. , Pandey, Ahwan , Ariyaratne, Dinuka , Laumont, Céline M. , Hamilton, Phineas T. , Alsop, Jennifer , Antoniou, Antonis C. , Au‐Yeung, George , Beckmann, Matthias W. , González, Amy Berrington de , Bisinotto, Christiani, Blome, Freya , Bodelón, Clara , Boros, Jessica , Brand, Alison H. , Carney, Michael E., Coulson, Penny , Cushing‐Haugen, Kara L. , Cybulski, Cezary, Darcy, Kathleen M. , David, C. W. Mabey, Davidson, Trent , Emons, Julius , Farrell, Rhonda , Gentry-Maharaj, Aleksandra, Harter, Philipp, Hartmann, Arndt, Heikaus, Sebastian, Hettiaratchi, Anusha , Heublein, Sabine , Huntsman, David G. , Jimenez-Linan, Mercedes , Jones, Michael E. , Kang, Eunyoung , Konecny, Gottfried E. , Kruitwagen, Rutgerus, Kwon, Jessica, Lambrechts, Diether , Lester, Jenny, Leung, Samuel , Leung, Yee , Loverix, Liselore , Mateoiu, Constantina , McNeish, Iain A. , Nevins, Nikilyn, Olawaiye, Alexander , Oršulić, Sandra , Osório, Ana , Quinn, Carmel M. , Mohan, Ganendra Raj , Ruebner, Matthias , Salfinger, Stuart , Samra, Spinder , Stewart, Colin J.R. , Talhouk, Aline , Tan, Adeline , Tarney, Christopher M., Aa, Maaike AVan Der, Gorp, Toon Van , Nieuwenhuysen, Els Van, Wagensveld, Lilian van , Wahner-Hendrickson, Andrea E., Walter, Christina B., Welz, Julia , Wentzensen, Nicolas , Winterhoff, Boris , Berchuck, Andrew, Fasching, Peter A. , Gayther, Simon A. , Kelemen, Linda E. , Maxwell, G. Larry , Menon, Usha , Modugno, Francesmary, Schildkraut, Joellen M. , Staebler, Annette , Swedlow, Anthony, Vergote, Ignace , Wu, Anna H. , Pearce, Celeste Leigh, Pike, M. C., Goode, Ellen L. , Bowtell, David D.L. , Lambrechts, Diether , Garsed, Dale W , Fereday, Sian , Pandey, Ahwan , Ariyaratne, Dinuka , Kennedy, Catherine J , Milne, Katy , Berrington de Gonzalez, Amy , Blome, Freya , Bodelon, Clara , Christie, Elizabeth L , Ekici, Arif B , Ghatage, Prafull , Hettiaratchi, Anusha , Jones, Michael E , Kommoss, Felix , Lambrechts, Diether , Lee, Cheng-Han , Leung, Yee , Linder, Anna , McNeish, Iain A , Nelson, Gregg S , Nevins, Nikilyn , Ray-Coquard, Isabelle L. , Roxburgh, Patricia , Van de Vijver, Koen , Wahner-Hendrickson, Andrea, Wang, Chen , Wentzensen, Nicolas , Winham, Stacey J , Anglesio, Michael S , Cohen, Paul , Conrads, Thomas , Fasching, Peter A , Horlings, Hugo , Karlan, Beth Y , Menon, Usha , Neuhausen, Susan L. , Brenton, James D , Pharoah, Paul D P , Goode, Ellen L , Ramus, Susan J , Köbel, Martin , Nelson, Brad H , Fazio, Anna de , Friedlander, Michael , Lambrechts, Diether , Brand, Alison H , Bowtell, David D , Goodman, Marc T , Zwimpfer, Tibor A. , Fereday, Sián , Jayawardana, Madawa , Twomey, Laura , Kennedy, Catherine J. , Bolithon, Adelyn , Meagher, Nicola S. , Milne, Katy , Cazorla, Alicia , Chiu, Derek S , Christie, Elizabeth L. , Chudecka-Glaz, Anita Monika , Ekici, Arif B. , Elishaev, Esther , Engler, Tobias , Fischer, Anna, García‐Closas, Montserrat , Gentry‐Maharaj, Aleksandra , Glasspool, Rosalind , Hartkopf, Andreas D , Hernandez, Brenda Y. , Kaznowska, Ewa B. , Kluz, Tomasz , Kruitwagen, Roy F.P.M. , Kwon, Jessica, Lee, Cheng‐Han , Lester, Jenny, Leung, Samuel, Linder, Anna , Lissowska, Jolanta , Lubiński, Jan , Moubarak, Malak , Nelson, Gregg , Olbrecht, Siel , Rodríguez‐Antona, Cristina , Schoemaker, Minouk J. , Sinn, Hans‐Peter , Sonke, Gabe S. , Steele, Linda, Taylor, Sarah E , Nieuwenhuysen, Els Van , Wang, Chen , Wilkens, Lynne R. , Winham, Stacey J. , Anglesio, Michael S. , Reis, Francisco José Cândido dos , Cohen, Paul A. , Crowe, Philip John , Doherty, Jennifer A. , Fortner, Renée T. , García, María J. , Goodman, Marc T. , Gronwald, Jacek , Harris, Holly R. , Heitz, Florian , Karlan, Beth Y. , Sundfeldt, Karin , Brenton, James D. , Pharoah, Paul D.P. , Ramus, Susan J. , Köbel, Martin , Nelson, Brad H. , DeFazio, Anna , Friedländer, Michael

Mayo Clinic

No container title available | October 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7572112/v1 | PMID 41255967 Get It

Abstract BRCA-associated homologous recombination deficiency (HRD) is present in ~ 50% of high-grade serous carcinomas (HGSC) and predicts sensitivity to platinum-based therapy. However, there is little understanding of why some patients with BRCA-deficient tumors experience unexpectedly poor outcomes. We profiled 154 tumors, enriched for patients with BRCA-deficient tumors that experienced short overall survival (≤ 3 years, n = 42), using whole-genome, transcriptome, and methylation analyses. All but one BRCA-deficient tumor exceeded an accepted HRD genomic scarring threshold. However, patients with BRCA1-deficient HGSC with a more elevated HRD score survived significantly longer. Patients with BRCA2-deficient HGSC and loss of NF1 survived twice as long as those without NF1 loss, whereas PIK3CA or RAD21 amplification defined BRCA2-deficient HGSC with exceptionally short survival. BRCA1-deficient tumors in short survivors had evidence of immunosuppressive c-kit signaling and EMT. In a large HGSC cohort (n = 1,389) including 282 individuals with pathogenic germline BRCA variants (gBRCApv), the location of the mutation within functional domains stratified clinical outcomes. Notably, residual disease after primary surgery had limited prognostic effect in gBRCApv-carriers compared to non-carriers. Our findings indicate that tumor HR proficiency in the context of therapy response and survival is not a binary property, and highlight genomic and immune modifiers of outcomes in BRCA-deficient HGSC.
P14.13.B TREATMENT OF RECURRENT ADAMANTINOMATOUS CRANIOPHARYNGIOMA WITH A COMBINATION OF BEVACIZUMAB AND TOCILIZUMAB: A CASE SERIES
Webb, Lauren M. , Trejo‐Lopez, Jorge , Celda, María Peris, Ruff, Michael W. , Sener, Uğur , Kaufmann, Timothy J. , Gompel, Jamie J. Van , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | October 3, 2025 | Volume: 27 | Issue: Supplement_3 | Pages: iii141-iii141

10.1093/neuonc/noaf193.474 Get It

Abstract BACKGROUND Adamantinomatous craniopharyngiomas (ACPs) are rare, partially cystic central nervous system tumors driven by the WNT/β-catenin pathway. As they grow, ACPs compress the surrounding pituitary gland, optic chiasm, and third ventricle. ACPs are highly morbid tumors with enormous quality of life impact on patients, often early in life. Thus, better treatments are needed. Current ACP treatment consists of maximally safe surgical resection with radiation for residual disease. Complete surgical resection is challenging, and recurrence is common. Targeted systemic chemotherapy is not routinely used for ACP treatment. Interleukin-6 (IL-6) levels are elevated within ACPs compared to normal brain tissue, making IL-6 an intriguing therapeutic target. Treatment response of ACP to tocilizumab alone or in combination with bevacizumab has been reported in children. MATERIAL AND METHODS We retrospectively reviewed the medical records of three adults with recurrent ACP who received combination treatment with bevacizumab and tocilizumab on a compassionate basis between June 2022 and April 2025 at Mayo Clinic in Rochester, MN. We collected demographic, clinical, treatment, radiologic, and outcome data. RESULTS All three patients were male and median age at initial ACP diagnosis was 38 years (range: 32-42 years). All patients underwent subtotal resection followed by radiation therapy. One patient had repeat surgical resection and two patients required interventions for hydrocephalus. At the time of ACP recurrence, all patients had visual impairment, endocrine dysfunction, and headaches. All patients received bevacizumab (7.5 mg/kg q3 weeks) and tocilizumab (8 mg/kg q3 weeks [n=2] or 4 mg/kg q4 weeks [n=1]). While receiving combination therapy, ACP tumor volume decreased on magnetic resonance imaging for all three patients (64%, 68%, and 29% reduction). None exhibited tumor growth since starting combination therapy. One patient had a small intraparenchymal hemorrhage, suspected secondary to radiation-induced cavernous malformation, so bevacizumab was discontinued, and he remains on tocilizumab alone. The other two patients continue combination therapy (for 344 and 351 days). Two patients experienced improvement in vision, and one had improvement in cognition. Possible adverse effects of treatment included sinus infections, fatigue, neutropenia, and hypertension. CONCLUSION Treatment with combination bevacizumab and tocilizumab was associated with shrinkage of ACP tumors and clinical improvements and obviated the need for further surgery or radiation in all three patients. This combination of medications may reprogram the tumor microenvironment, leading to ACP involution. This well-tolerated regimen provides a noninvasive option for treatment of recurrent ACP, and potentially initial ACP treatment, and may improve quality of life for patients.
Sinonasal Sarcomas Management: An International Consensus Statement
Caspani, F , Camarda, Anna Maria , Provenzano, Salvatore , Meço, Cem , Ferrari, Marco , Harrabi, Semi , Hosni, Ali, Italiano, Antoine, Vérillaud, Benjamin , Castelnuovo, Paolo, Nicolai, Piero, Su, Shirley Y. , Eloy, Jean Anderson , Fiore, Maria Rosaria, Palmer, James, Oliden, Victor Castro , Tos, Angelo Paolo Dei , Casali, Paolo G. , Dufresne, Armelle , Orlandi, Ester , Wormald, Peter‐John, Herman, Philippe , Carrau, Ricardo, Hanna, Ehab Y., Provenzano, Salvatore , Wang, Eric W , Ferrari, Marco , Schreiber, Alberto , Lechner, Matt , Eloy, Jean Anderson , Georgalas, Christos , Turri-Zanoni, Mario , Meço, Cem , Su, Shirley Y , Vinciguerra, Alessandro , Valentini, Marco , Šurda, Pavol , Campos, Fernando Augusto Batista , Martín‐Broto, Javier , Guadagnolo, B. Ashleigh , Navarria, Pierina , Hindi, Nadia , Italiano, Antoîne , Trifiletti, Daniel M. , Kasper, Bernd , Schreiber, Alberto , Castelnuovo, Paolo, Nicolai, Piero , Dallan, Iacopo , Chacón, Matías , Thariat, Juliette , Valverde, Claudia María , Lechner, Matt , Blay, Jean‐Yves , Brahmi, Mehdi , Greto, Daniela , Lugowska, Iwona A. , van Zele, Thibaut , Psaltis, Alkis J. , Sangalli, Claudia , Wormald, Peter‐John , Hanna, Ehab Y., Licitra, Lisa , Turri‐Zanoni, Mario , Battaglia, Paolo

Mayo Clinic

International Forum of Allergy & Rhinology | September 30, 2025 | Volume: 16 | Issue: 1 | Pages: 55-69

10.1002/alr.70038 | PMID 41025537 Get It

ABSTRACT Introduction Sinonasal sarcomas are exceedingly rare entities, constituting less than 7% of head and neck sarcomas. Their complex histology needs specialized treatment, which is often based on multimodal approaches including surgery, radiation therapy, and/or chemotherapy. This manuscript aims to gather expert opinions to establish common management principles for sinonasal sarcomas. Methods This international consensus followed a modified Delphi method in seven steps, including statements definition by the core group, expert panel recruitment, and a two‐round survey. Sixty‐two statements on sinonasal sarcoma management were developed. Experts from multiple continents participated, and results were anonymized and analyzed between March and May 2025. Results A total of 44 invited experts were recruited, 43.2% otorhinolaryngologists/head and neck surgeons, 31.8% medical oncologists, and 25% radiation oncologists. Participants varied in age and experience, representing Europe (70.5%), North America (18.2%), South America (6.8%), and Asia (4.5%). Among all histologies, biphenotypic sarcoma, chondrosarcoma, leiomyosarcoma, and myofibrosarcoma are principally treated with an upfront surgical management, differently from Ewing sarcoma and rhabdomyosarcoma in which chemotherapy, eventually associated with radiotherapy, is often chosen. In the remaining histologies (angiosarcoma, liposarcoma, malignant peripheral nerve sheath tumor [MPNST], osteosarcoma, and synovial sarcoma), a precise multimodal treatment is less standardized and needs to be discussed on a case‐by‐case basis. Conclusion Sinonasal sarcomas require a histology‐driven approach to determine upfront treatment, whether surgical, medical, or multimodal. Despite this structured strategy, prognosis remains highly variable across subtypes. Multidisciplinary evaluation and individualized management in referral centers are crucial to address the biological diversity and anatomical complexity of these rare malignancies.
Delirium Around the World: Performing An International Point Prevalence Study Increases Awareness for Delirium
Castro, Roberta, Liu, Keibun , Haken, Rebecca von , Avelino‐Silva, Thiago Junqueira , Nawa, Ricardo Kenji , Collet, Marie Oxenbøll , Timmons, Suzanne , Bellelli, Giuseppe , Boogaard, Mark van den , Mailhot, Tanya , Morandi, Alessandro , Wøien, Hilde , Alhammad, Abdullah , Lindroth, Heidi , Nydahl, Peter

Mayo Clinic

Delirium | September 29, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.56392/001c.141065 Get It

Background Global efforts to raise delirium awareness have been made over the past years, such as the formation of the iDelirium group and the institution, in 2017, of the annual World Delirium Awareness Day (WDAD) in March. In 2023, our group and researchers from around the world conducted a global one-day point prevalence study of delirium on WDAD. These strategies appear to improve delirium recognition and management. Objective To assess participants’ perceived impact of participating in the WDAD 2023 one-day point prevalence study and to gather feedback on the survey process to inform future campaigns. Methods An online survey was administered to multiple national and clinical collaborators from 44 countries participating in the one-day global point delirium prevalence study on WDAD 2023. Using SurveyMonkey®, the survey was distributed via a snowball system, with participants’ consent implied through their involvement. The survey, developed iteratively to balance time and detail, consisted of six core questions, including closed and open formats. Data were collected from September 9th to October 9th, 2023, and qualitative and quantitative analyses were performed using Excel®. Quantitative data underwent statistical analysis using IBM® SPSS Statistics28. Results 49 out of 53 (93.45%) healthcare professionals responded to the survey: 71.43% reported increased awareness, and responses were almost equally divided between those who initiated projects (46.94%) and those who did not (53.06%). Most participants (93.88%) did not find the WDAD 2023 one-day point prevalence study in March burdensome, and all expressed interest in future participation. The WDAD 2023 one-day point prevalence study highlighted diverse projects, primarily focused on delirium awareness and education. The survey found suggestions for future improvements emphasizing more efficient, digital, and engaging research methods and a clear need for educational resources, particularly in ICU delirium. Conclusions Our survey finds that participation in WDAD 2023 one-day point prevalence study boosted delirium visibility, leading to ongoing awareness, interest in future studies, and practice changes that benefit patients and the healthcare system. Further evidence-based research is needed to assess the impact of these campaigns on delirium recognition and management.
Physical activity and molecular subtypes of colorectal cancer: a pooled observational analysis and Mendelian randomization study
Chalitsios, Christos V. , Markozannes, Georgios , Aglago, Elom K. , Berndt, Sonja I., Buchanan, Daniel D. , Campbell, Peter T. , Chan, Andrew T. , Dimou, Niki , Drew, David A. , French, Amy J. , Georgeson, Peter , Giannakis, Marios , Gruber, Stephen B., Harrison, Tabitha A. , Hullar, Meredith A.J. , Huyghe, Jeroen R. , Newton, Christina C. , Schmit, Stephanie L. , Steinfelder, Robert S. , Ugai, Tomotaka, Zaidi, Syed Hassan Ejaz , Woods, Michael O. , Andreson, Laura, Peters, Ulrike , Phipps, Amanda I , Tsilidis, Konstantinos K, Berndt, Sonja I , Cao, Yin , Chan, Andrew T , Dimou, Niki , Drew, David A , Georgeson, Peter , Giannakis, Marios , Gruber, Stephen B , Harrison, Tabitha A , Hoffmeister, Michael , Hsu, Li , Huang, Wen-Yi , Hullar, Meredith A , Huyghe, Jeroen R , Lynch, Brigid M , Moreno, Victor , Newton, Christina C , Nowak, Jonathan A , Obón-Santacana, Mireia , Ogino, Shuji , Schmit, Stephanie L , Steinfelder, Robert S , Sun, Wei , Thomas, Claire E , Toland, Amanda Ewart , Trinh, Quang M , Ugai, Tomotaka , Um, Caroline Y , Van Guelpen, Bethany , Schoen, Robert E , Woods, Michael O , Brenner, Hermann , Anderson, Laura , Pellatt, Andrew J , Phipps, Amanda I , Tsilidis, Konstantinos K , Buchanan, Daniel D , Campbell, Peter T , Aglago, Elom K , Markozannes, Georgios , Berndt, Sonja I. , Gunter, Marc J. , Hoffmeister, Michael , Huang, Wen‐Yi , Moreno, Vı́ctor , Murphy, Neil , Nowak, Jonathan A. , Obón‐Santacana, Mireia , Qu, Conghui , Sun, Wei , Thomas, Claire E. , Trinh, Quang M. , Um, Caroline Y. , Guelpen, Bethany Van , Schoen, Robert E. , Brenner, Hermann , Pellatt, Andrew J. , Tsilidis, Konstantinos K.

Mayo Clinic

JNCI Cancer Spectrum | September 29, 2025 | Volume: 9 | Issue: 6 | Pages: No page available

10.1093/jncics/pkaf095 | PMID 41031512 Get It

Abstract Background Physical activity is associated with lower colorectal cancer (CRC) risk, but its association with molecular subtypes defined by genetic and epigenetic alterations of the disease is unclear. Such information may enhance the understanding of the mechanisms related to the benefits of physical activity. Methods Pooled observational (cases: n = 5386; controls: n = 6798; studies n = 5) and genome-wide association data (cases: n = 8178; controls: n = 10 472; studies n = 5) were used. We used multivariable logistic regression models and Mendelian randomization to assess the association between physical activity and the risk of CRC subtypes defined by individual tumor markers (and marker combinations), namely microsatellite instability status, CpG island methylator phenotype status, and BRAF and KRAS mutations. We used case-only analysis to test for differences between molecular subtypes. We applied Bonferroni correction to account for multiple tests. Results In the pooled observational analysis, higher levels of physical activity were associated with lower CRC risk (Obs-per 1SD, odds ratio [OR] = 0.94, 95% confidence interval [CI] = 0.90 to 0.97), with an association that was stronger in males (Obs-per 1SD, OR = 0.91, 95% CI = 0.87 to 0.96) than in females (Obs-per 1SD, OR = 0.97, 95% CI = 0.91 to 1.03; Pinteraction = .04). Higher physical activity was associated with a lower risk of CRC across all molecular subtypes, especially in males. There was no difference in the associations by subtypes by pooled observational or Mendelian randomization analyses. The findings did not differ by study design, anatomical site, and early or late age onset of CRC. Conclusions Our findings suggest that physical activity is not differentially associated with the 4 major molecular subtypes involved in colorectal carcinogenesis, indicating that its benefits extend broadly across colorectal cancer pathogenesis.
Poster 132: Smokeless Tobacco Use is Associated with Increased Perioperative Complications and Revision Surgery After Anterior Cruciate Ligament Reconstruction
Pejic, Jelena , Schuyver, Paul Van , Holle, Alejandro M. , Tummala, Sailesh V. , Chhabra, Anikar , Economopoulos, Kostas J.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | September 26, 2025 | Volume: 13 | Issue: 9_suppl3 | Pages: No page available

10.1177/2325967125s00229 Get It

Objectives: Tobacco use is a known modifiable risk factor for postoperative complications and revision surgery after anterior cruciate ligament reconstruction (ACLR). Prior studies focus on “tobacco” as a broad categorization of traditional cigarette smoking, smokeless tobacco, and other forms of nicotine use. It is unclear if differences in the type of nicotine used lead to similar adverse outcomes after ACLR. Thus, the purpose of this study was to (1) assess the incidence of postoperative complications among ACLR patients who use smokeless tobacco, and (2) compare these outcomes with those of patients who do not use tobacco and those who smoke cigarettes. Methods: A retrospective cohort study utilizing a large insurance database was conducted. Patients undergoing primary ACLR without concomitant knee procedures with a minimum 2-year follow-up were included. Smokeless tobacco only users, cigarette only users, and non-tobacco users were matched based on demographic variables and comorbidities. Postoperative complications within 90 days of surgery and subsequent knee surgery within 2 years were compared among groups. Multivariable logistic regressions were employed to control for confounding variables. Results: After applying exclusion criteria, there were 241,194 ALCR patients eligible for analysis. Of these, there were 898 (0.37%) patients that used smokeless tobacco only, 22,062 (9.1%) patients that exclusively used cigarettes, and 207,462 (86%) patients that did not use any tobacco products. Compared to non-users, smokeless tobacco users demonstrated increased risk of emergency department (ED) utilization (20.4% vs 8.7%, OR: 6.29; 95% CI: 3.70-10.9, p<0.001), pneumonia (1.2% vs 0.5%, OR: 3.36; 95% CI: 1.41-7.90, p=0.005), and acute kidney injury (AKI) (1.2% vs 0.1%, OR:12.7; 95% CI: 3.77-52.8, p<0.001) within 90 days of surgery. Additionally, smokeless tobacco users had a markedly increased risk of subsequent ACLR (13.5% vs 3.2%, OR: 4.75; 95% CI: 3.60-6.26, p<0.001) and meniscus surgery (12.9% vs 4.9%, OR: 2.89; 95% CI: 2.23-3.73, p<0.001) within 2 years compared to controls. When compared to cigarette smokers, smokeless tobacco users showed increased risk of ED visits (20.6% vs 19.3%, OR: 1.55; 95% CI: 1.25-1.90, p<0.001), pneumonia (1.2% vs 0.6%, OR: 3.25; 95% CI: 1.33-7.78, p=0.008), and AKI (1.3% vs 0.3%, OR: 7.63; 95% CI: 2.72-22.5, p<0.001) within 90 days. They also demonstrated a significantly increased risk of subsequent ACLR (13.4% vs 4.1%, OR: 4.81; 95% CI: 3.58-6.47, p<0.001) and meniscus surgery (12.8% vs 5.5%, OR: 2.45; 95% CI: 2.45-4.26, p<0.001) within 2 years when compared to cigarette smokers. Conclusions: Smokeless tobacco use was associated with increased risk of medical complications, ED utilization, and subsequent procedures compared to non-user controls and traditional smokers. These findings highlight the importance of considering specific forms of tobacco use in preoperative screening for patients undergoing ACLR.
21: Characteristics of Survivors of High-Risk Pulmonary Embolism Receiving Veno-Arterial Extracorporeal Membrane Oxygenation: A Meta-Analysis
Buda, Kevin, Baldetti, Luca, Garcia, Samuel, Basir, Mir, Gage, Ann, Van-Hove, Christopher, Bennett, Mosi, Melamed, Roman, Megaly, Michael, Skeik, Nedaa, Hryniewicz, Katarzyna, Buda, Kevin, Baldetti, Luca, Garcia, Samuel, Basir, Mir, Gage, Ann, Van-Hove, Christopher, Bennett, Mosi, Melamed, Roman, Megaly, Michael, Skeik, Nedaa, Hryniewicz, Katarzyna

Mayo Clinic

ASAIO Journal | September 26, 2025 | Volume: 71 | Issue: Supplement 4 | Pages: 3-3

10.1097/01.mat.0001168808.58116.f4 Get It